Based on this information, Crews’ group studied the possibility of a PROTAC targeting BTK, using an ibrutinib analogue as TLM, for its effectiveness in treating CLL with C418S BTK.108. Here, BTK is linked to B-cell chronic lymphocytic leukemia.